Kiniksa Pharmaceuticals International (KNSA) Current Assets (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Current Assets came in at $668.6 million in Q2 2026, up 59.08% YoY from $420.3 million in Q2 2025, and up 12.53% on a QoQ basis from $594.2 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Current Assets (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Current Assets data on file, last reported at $668.6 million in Q2 2026.
- Quarterly Current Assets rose 59.08% year-over-year to $668.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $668.6 million (up 59.08% YoY) and the FY2025 annual result came in at $527.2 million, up 58.88% from the prior year.
- Current Assets advanced to $668.6 million in Q2 2026, from $594.2 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $668.6 million in Q2 2026 to a low of $179.9 million in Q2 2022.
- A 5-year average of $340.6 million and a median of $288.7 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets decreased 27.87% — and 2026, when it soared 66.95%.
- Tracing KNSA's Current Assets over 5 years: stood at $243.1 million in 2022, then grew by 13.67% to $276.3 million in 2023, then increased by 20.09% to $331.8 million in 2024, then soared by 58.88% to $527.2 million in 2025, then advanced by 26.83% to $668.6 million in 2026.
- The last three Current Assets figures came in at $668.6 million (Q2 2026), $594.2 million (Q1 2026), and $527.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 5.76 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 13.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 6.36 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 19.76 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 3.48 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 10.06 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.64 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.80 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 3.22 Bn |
| 10 | Kiniksa Pharmaceuticals International | 6.05 Bn | 5.52 Bn | 220.03 Mn | 668.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 668.63 Mn |
| Mar 31, 2026 | 594.17 Mn |
| Dec 31, 2025 | 527.18 Mn |
| Sep 30, 2025 | 475.53 Mn |
| Jun 30, 2025 | 420.31 Mn |
| Mar 31, 2025 | 355.91 Mn |
| Dec 31, 2024 | 331.80 Mn |
| Sep 30, 2024 | 311.30 Mn |
| Jun 30, 2024 | 301.02 Mn |
| Mar 31, 2024 | 270.59 Mn |
| Dec 31, 2023 | 276.30 Mn |
| Sep 30, 2023 | 256.11 Mn |
| Jun 30, 2023 | 246.04 Mn |
| Mar 31, 2023 | 231.50 Mn |
| Dec 31, 2022 | 243.06 Mn |
| Sep 30, 2022 | 241.82 Mn |
| Jun 30, 2022 | 179.94 Mn |
| Mar 31, 2022 | 198.76 Mn |
| Dec 31, 2021 | 196.45 Mn |
| Sep 30, 2021 | 217.51 Mn |